该公司的研发管线包括旨在抑制RAS蛋白的各种致癌变异的RAS(ON)抑制剂,以及用于联合治疗策略的RAS伴侣抑制剂。该公司的RAS(ON)抑制剂RMC-6236(RAS多), RMC-6291 (克拉斯)G12C) 和 RMC-9805 (KRAS)G12D)目前正在临床开发中。该公司产品线中的其他RAS(ON)抑制剂包括RMC-0708(KRAS问61H) 和 RMC-5127 (KRAS)...
(KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-0708 (KRASQ61H) and RMC-5127 (KRASG12V) which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional ...